Viewing Study NCT05088967

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 12:32 AM
Ignite Modification Date: 2025-12-31 @ 6:08 PM
Study NCT ID: NCT05088967
Status: TERMINATED
Last Update Posted: 2024-01-16
First Post: 2021-09-28
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in Neoadjuvant and Adjuvant Therapy of Radically Resectable Non-small Cell Lung Cancer
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Non-small Cell Lung Cancer (NSCLC) View
Keywords: